Table 1.
Baseline clinicopathological characteristics categorized by overall population, EGFR, and PD-L1 (SP263) status
| Characteristics | Overall population (n = 441) | EGFR (n = 332) | P value | PDL1 SP263 (n = 259) | P value | ||
|---|---|---|---|---|---|---|---|
| Negative (n = 140) | Positive (n = 192) | Negative (n = 206) | ≥ 1 (n = 53) | ||||
| Sex | |||||||
| Male | 160 (36%) | 63 (44%) | 56 (30%) | 0.007 | 63 (31%) | 24 (45%) | 0.043 |
| Female | 281 (64%) | 80 (56%) | 133 (70%) | 143 (69%) | 29 (55%) | ||
| Age, years | |||||||
| < 65 | 137 (31%) | 41 (29%) | 62 (32%) | 0.559 | 61 (30%) | 19 (36%) | 0.381 |
| ≥ 65 | 304 (69%) | 99 (71%) | 130 (68%) | 145 (70%) | 34 (64%) | ||
| COPD | 36 (8%) | 20 (14%) | 8 (4%) | 0.001 | 11 (5%) | 8 (15%) | 0.033 |
| Smoking | |||||||
| Never | 212 (48%) | 56 (40%) | 104 (54%) | < 0.001 | 108 (52%) | 23 (43%) | 0.085 |
| Former/Current | 123 (28%) | 54 (39%) | 36 (19%) | 47 (23%) | 20 (38%) | ||
| ECOG | |||||||
| 0–1 | 339 (77%) | 117 (84%) | 146 (76%) | 0.095 | 162 (79%) | 42 (79%) | 0.924 |
| Unknown | 102 (23%) | 23 (16%) | 46 (24%) | 44 (21%) | 11 (21%) | ||
| CEA | |||||||
| < 3.8 ng/ml | 141 (32%) | 47 (34%) | 61 (32%) | 0.881 | 71 (16%) | 13 (25%) | 0.127 |
| ≥ 3.8 ng/ml | 80 (18%) | 24 (17%) | 31 (16%) | 29 (7%) | 13 (25%) | ||
| Surgery procedure | |||||||
| Lobectomy | 377 (85%) | 117 (84%) | 164 (85%) | 0.645 | 173 (84%) | 48 (91%) | 0.227 |
| Wedge resection or segmentectomy | 64 (15%) | 23 (16%) | 28 (15%) | 33 (16%) | 5 (9%) | ||
| Pathology | |||||||
| Adenocarcinoma | 415 (94%) | 128 (92%) | 187 (97%) | 0.017 | 196 (95%) | 51 (96%) | 1 |
| Adenosquamous | 23 (5%) | 9 (6%) | 5 (3%) | 9 (4%) | 2 (4%) | ||
| NSCLC, NOS | 3 (1%) | 3 (2%) | 0 | 1 (1%) | 0 | ||
| HIstology subtype | |||||||
| MIA | 13 (3%) | 3 (2%) | 2 (1%) | < 0.001 | 3 (1%) | 1 (2%) | < 0.001 |
| Lepidic | 106 (24%) | 26 (19%) | 47 (24%) | 56 (27%) | 5 (9%) | ||
| Acinar | 192 (44%) | 42 (30%) | 104 (54%) | 92 (45%) | 21 (40%) | ||
| Papillary | 38 (9%) | 10 (7%) | 21 (11%) | 20 (10%) | 7 (13%) | ||
| Micropapillary | 15 (3%) | 9 (6%) | 5 (3%) | 5 (2%) | 2 (4%) | ||
| Solid | 26 (6%) | 15 (11%) | 6 (3%) | 4 (2%) | 9 (17%) | ||
| Mucinous | 33 (7%) | 24 (17%) | 4 (2%) | 20 (10%) | 3 (6%) | ||
| pT | |||||||
| T1 | 246 (56%) | 71 (51%) | 106 (55%) | 0.012 | 117 (57%) | 27 (51%) | 0.861 |
| T2a | 99 (22%) | 24 (17%) | 52 (27%) | 45 (22%) | 14 (26%) | ||
| T2b | 31 (7%) | 12 (8%) | 14 (7%) | 14 (7%) | 4 (8%) | ||
| T3 | 52 (12%) | 25 (18%) | 16 (24%) | 25 (12%) | 6 (11%) | ||
| T4 | 13 (3%) | 8 (6%) | 4 (2%) | 5 (2%) | 2 (4%) | ||
| pN | |||||||
| N0 | 365 (82%) | 115 (82%) | 150 (78%) | 0.756 | 175 (85%) | 34 (64%) | 0.003 |
| N1 | 38 (9%) | 11 (8%) | 20 (10%) | 13 (6%) | 6 (11%) | ||
| N2 | 38 (9%) | 14 (10%) | 22 (11%) | 18 (9%) | 13 (25%) | ||
| Margin | |||||||
| Negative | 429 (97%) | 135 (96%) | 185 (96%) | 0.971 | 199 (97%) | 51 (96%) | 1 |
| Positive | 12 (3%) | 5 (4%) | 7 (4%) | 7 (3%) | 2 (4%) | ||
| LVI | |||||||
| Negative | 284 (64%) | 84 (60%) | 120 (63%) | 0.871 | 141 (68%) | 25 (47%) | 0.006 |
| Positive | 142 (32%) | 52 (37%) | 66 (34%) | 58 (23%) | 26 (49%) | ||
| Pleural invasion | |||||||
| Negative | 292 (66%) | 88 (63%) | 125 (65%) | 0.335 | 132 (64%) | 32 (60%) | 0.031 |
| Positive | 113 (26%) | 41 (29%) | 45 (23%) | 47 (23%) | 16 (30%) | ||
| Pathological staging | |||||||
| I | 301 (68%) | 80 (57%) | 132 (69%) | 0.061 | 145 (70%) | 26 (49%) | 0.003 |
| II | 82 (19%) | 37 (27%) | 32 (17%) | 36 (18%) | 11 (21%) | ||
| III | 58 (13%) | 23 (16%) | 28 (14%) | 25 (12%) | 16 (30%) | ||
| Adjuvant systemic treatment | |||||||
| Cisplatin-based | 45 (10%) | 16 (11%) | 26 (14%) | 0.194 | 19 (9%) | 11 (21%) | 0.122 |
| Carboplatin-based | 44 (10%) | 17 (12%) | 15 (8%) | 17 (8%) | 6 (11%) | ||
| Others | 5 (1%) | 2 (1%) | 3 (2%) | 3 (1%) | 1 (2%) | ||
| Unknown | 3 (1%) | 3 (2%) | 0 | 2 (1%) | 0 | ||
| Adjuvant radiation | |||||||
| RT alone | 2 (0.5%) | 2 (1%) | 0 | 0.292 | 0 | 2 (4%) | 0.005 |
| CCRT | 6 (1%) | 1 (0.7%) | 4 (2%) | 4 (2%) | 1 (2%) | ||
| Sequential | 17 (14%) | 8 (6%) | 8 (4%) | 7 (3%) | 6 (11%) | ||
| Recurrent | |||||||
| Locoregional | 20 (5%) | 10 (7%) | 9 (5%) | 0.585 | 41 (20%) | 16 (30%) | 0.229 |
| Distant metastasis | 99 (22%) | 39 (28%) | 51 (27%) | 9 (4%) | 3 (6%) | ||
| CNS metastasis | 19 (4%) | 6 (4%) | 11 (6%) | 0.556 | 5 (2%) | 4 (8%) | 0.088 |
pT pathological tumor stage, pN pathological nodal stage, LVI Lymphovascular invasion, RT Radiation, CCRT Concurrent radiation, NA not available